2020
Erythrocyte membrane fatty acids and breast cancer risk by tumor tissue expression of immuno-inflammatory markers and fatty acid synthase: a nested case-control study
McGee EE, Kim CH, Wang M, Spiegelman D, Stover DG, Heng YJ, Collins LC, Baker GM, Farvid MS, Schedin P, Jindal S, Tamimi RM, Eliassen AH. Erythrocyte membrane fatty acids and breast cancer risk by tumor tissue expression of immuno-inflammatory markers and fatty acid synthase: a nested case-control study. Breast Cancer Research 2020, 22: 78. PMID: 32698885, PMCID: PMC7374956, DOI: 10.1186/s13058-020-01316-4.Peer-Reviewed Original ResearchConceptsBreast cancer riskImmuno-inflammatory markersErythrocyte membrane fatty acidsCase-control studyTumor tissue expressionFatty acid synthaseCancer riskTrans fatty acidsExpression subtypesOdds ratioSpecific fatty acidsLogistic regressionHealth Study IITumor tissue blocksMembrane fatty acidsFatty acidsUnconditional logistic regressionConfidence intervalsTissue expressionT cell functionPolytomous logistic regressionAcid synthaseTumor CD4Potential confoundersTumor expression
1999
The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer.
Haiman CA, Hankinson SE, Spiegelman D, Colditz GA, Willett WC, Speizer FE, Kelsey KT, Hunter DJ. The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer. Cancer Research 1999, 59: 1015-20. PMID: 10070957.Peer-Reviewed Original ResearchConceptsHealth Study cohortBreast cancer riskBreast cancerHormone levelsA2 alleleCancer riskNurses' Health Study cohortStrong independent risk factorA2/A2 genotypeCYP17 A2 alleleElevated levelsAdvanced breast cancerIncident breast cancerIndependent risk factorPolycystic ovarian syndromeCertain steroid hormonesA1/A1 genotypeCase-control studyPlasma hormone levelsSteroid hormone levelsLater agePremenopausal womenCYP17 genotypeHormone replacementOvarian syndrome